Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-4047 in Metastatic Hormone Refractory Prostate Cancer
NCT00072722Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2003
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pomalidomide in prostate cancer (PCa) (2 cohorts), sponsored by Celgene Corporation. Primary endpoints: Prostate-Specific Antigen Response and Safety and Tolerability. Started Sep 2003; status: completed.
02
Drugs
pomalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00072722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072722.